ZYMAR
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYMAR is an ophthalmic antibiotic solution approved in 2003 for bacterial eye infections. Administered as topical drops, it delivers small-molecule antimicrobial therapy directly to the ocular surface. The product treats common bacterial conjunctivitis and other external eye infections in both pediatric and adult populations.
LOE Approaching
As a mature ophthalmic product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension and margin optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose
Started Jun 2006
40 enrolled
Eye InfectionInfection
Career Relevance
Working on ZYMAR offers limited career growth potential given its mature, LOE-approaching status and zero linked job opportunities. Positions on this brand focus on defensive commercial strategies, payer management, and market maintenance rather than product growth or innovation.
Brand Manager
Worked on ZYMAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.